Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2009

View Archived Issues

Naltrexone implant shown to be safe and effective in heroin dependence

Novel bacterial signal transduction inhibitors in development at Kinki University

France grants marketing authorization to Sanofi's Panenza influenza vaccine

Exclusive licensing agreement signed to market Zolpimist in U.S. and Canada

FDA approves NeurogesX's Qutenza for neuropathic pain due to postherpetic neuralgia

ARCA biopharma to submit study protocol for Gencaro trial under the FDA's SPA

PPD and Janssen to develop two phase II drugs for IBS-D and bacterial infections

Novartis reports interim data from ongoing clinical trials of influenza A vaccine

GP Pharm files NDA for Lutrate in five European countries

Data from phase III trials support safety and efficacy of tenofovir DF in CHB patients

Clinical data reported for boceprevir plus PegIntron/ribavirin in HCV

Rifaximin exhibits durable long-term protection in hepatic encephalopathy trial

Clinical data presented from 3 trials on sorafenib for HCC therapy

Cosmo Pharmaceuticals offers to acquire BioXell

Phase I data on JNJ-26483327 in solid tumors reported at 2009 AACR-NCI-EORTC meeting

Gruenenthal presents a new series of ORL1 and mu-opioid receptor ligands

Glucokinase activators for the treatment of diabetes described by Merck KGaA

FDA approves GlaxoSmithKline's pandemic H1N1 vaccine

New mGluR2 receptor ligands for the treatment of epilepsy disclosed by sanofi-aventis

Genentech submits sBLAs to FDA for first-line Avastin treatment of breast cancer

NeuroSearch claims novel dopamine and serotonin receptor modulators

Medical Therapies becomes Cellmid

Sequella and NIH sign new exclusive worldwide licensing agreement for SQ-109

FDA committee to review OSI's Tarceva as first-line maintenance therapy for NSCLC

FDA grants EUA to Roche's RealTime Ready Influenza A/H1N1 Detection Set

FDA accepts for filing NicOx's NDA for naproxcinod in osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...